Alzamend Neuro's AL001 shows promising safety and efficacy in Phase IIA trial for Alzheimer's Disease, advancing lithium therapy without traditional monitoring.
Read more
BioVersys completes Phase 2 trial of BV100 for Ventilator-Associated Bacterial Pneumonia, showing safety and efficacy against Carbapenem-Resistant Acinetobacter baumannii.
Read more
Akeso's Phase 3 trial shows cadonilimab significantly improves progression-free and overall survival in Cervical Cancer, published in The Lancet.
Read more
Marinus Pharmaceuticals' Phase 3 RAISE trial shows IV ganaxolone rapidly ceases Status Epilepticus in refractory patients, meeting one co-primary endpoint.
Read more
ViiV Healthcare's Apretude (cabotegravir long-acting) shows over 99% effectiveness in real-world studies for HIV pre-exposure prophylaxis, reducing stigma and anxiety, as presented at IDWeek 2024.
Read more
Merck's clesrovimab shows promise in reducing RSV-related infections and hospitalizations in infants, challenging Sanofi and AstraZeneca's Beyfortus.
Read more
Factor Bioscience and Eterna Therapeutics partner to advance cell therapies for Oncology, Autoimmune, and Rare Diseases using iPSC technology.
Read more
Pfizer partners with Triana Biomedicines in a $1.5B deal to develop molecular glue degraders for cancer and other diseases.
Read more
Sanofi and Orano Med partner to develop radioligand therapies for rare cancers using lead-212 isotopes.
Read more
Tonix Pharmaceuticals receives initial payment from U.S. Department of Defense for developing broad-spectrum antivirals under a $34 million contract.
Read more
FDA approves VYALEVâ„¢ for continuous subcutaneous infusion to manage motor fluctuations in advanced Parkinson's Disease.
Read more
Valneva and LimmaTech's tetravalent Shigella vaccine candidate receives FDA Fast Track designation to expedite development for Shigellosis prevention.
Read more
Novocure's Tumor Treating Fields receives FDA approval for metastatic non-small cell lung cancer, marking a significant survival improvement.
Read more
New genomic study identifies unique mutations in Black patients with Acute Myeloid Leukemia, challenging existing risk frameworks.
Read more
Avacta introduces AVA6103 and AVA7100, novel pre|CISION®-enabled oncology assets, enhancing targeted cancer treatment with reduced systemic toxicity.
Read more
Cullinan Therapeutics' CLN-978 receives FDA IND clearance for Phase 1 trial in Systemic Lupus Erythematosus.
Read more
Latigo Biotherapeutics initiates Phase 1 trial of LTG-305, a non-opioid Nav1.8 inhibitor, for chronic pain treatment.
Read more
Wave Life Sciences reports first therapeutic RNA editing in humans for Alpha-1 Antitrypsin Deficiency, boosting stock by 63%.
Read more
Wave Life Sciences achieves first therapeutic RNA editing in humans with WVE-006 for Alpha-1 Antitrypsin Deficiency in RestorAATion-2 trial.
Read more
Horizon Surgical Systems secures $30M in Series A funding to advance AI-enabled robotic microsurgery for ophthalmic applications.
Read more
Antiverse secures £3.5M to enhance AI-driven antibody design platform targeting GPCRs and ion channels.
Read more
Quest Diagnostics completes acquisition of OhioHealth lab assets to expand cost-effective laboratory services in Ohio.
Read more
The global diabetes drug market is projected to reach $107 billion by 2032, driven by new product approvals and increasing prevalence of Diabetes Mellitus.
Read more
Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion, enhancing its pipeline with bexicaserin for Developmental and Epileptic Encephalopathies.
Read more
NYU Langone appoints Dr. Shridar Ganesan to lead a new Molecular Oncology program, focusing on personalized cancer treatment through advanced molecular diagnostics.
Read more
